Here are six quick facts on the transaction:
• 15,000 shares were sold
• Average share price was $45.53
• Total transaction value was $682,950
• Mr. Miles now directly owns 84,651 shares
• His shares are valued at around $3.8 million
The company traded down on Tuesday 0.87 percent, according to the report. NuVasive’s 52-week low is $31.35. Many new reports, including one from a Canaccord Genuity, place NuVasive stock at a “buy” rating.
More articles on orthopedic devices:
Double-digit growth for Precision Spine in 2014—5 key updates
SpineGuad gets FDA thumbs-up for PediGuard
K2M sets follow-on offering at $18.75 per share — 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
